According to the report on the results of those trials, 100 percent of the 20 participants have shown antibodies to the SARS-CoV-2 virus spike protein (S-protein).
Trials in Azerbaijan began in February 2021 and to date, 64 volunteers have been vaccinated with the combined vaccine candidate.
Earlier trials also showed high safety indicators for the combined use of Sputnik Light, developed by Russia, and AstraZeneca, co-developed at the University of Oxford, in the United Kingdom.
No serious side effects or cases of coronavirus contagion after vaccination have been reported, the RDIF stated.
A clinical trial of the combination of vaccines is currently being implemented in several countries, as part of a global program, among them the United Arab Emirates and Argentina, and a regulatory approval to conduct trials has been granted in Russia and Belarus.